Galectin End Period Cash Flow from 2010 to 2024

GALT Stock  USD 3.23  0.09  2.87%   
Galectin Therapeutics End Period Cash Flow yearly trend continues to be comparatively stable with very little volatility. End Period Cash Flow will likely drop to about 13.8 M in 2024. From the period from 2010 to 2024, Galectin Therapeutics End Period Cash Flow quarterly data regression had r-value of  0.47 and coefficient of variation of  72.66. View All Fundamentals
 
End Period Cash Flow  
First Reported
2001-03-31
Previous Quarter
25.7 M
Current Value
23.6 M
Quarterly Volatility
13.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin main balance sheet or income statement drivers, such as Depreciation And Amortization of 44.8 K, Selling General Administrative of 5.3 M or Other Operating Expenses of 40 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0021 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
  
This module can also supplement Galectin Therapeutics' financial leverage analysis and stock options assessment as well as various Galectin Therapeutics Technical models . Check out the analysis of Galectin Therapeutics Correlation against competitors.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Latest Galectin Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Galectin Therapeutics over the last few years. It is Galectin Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Galectin End Period Cash Flow Regression Statistics

Arithmetic Mean18,695,775
Geometric Mean11,861,536
Coefficient Of Variation72.66
Mean Deviation11,030,580
Median15,362,000
Standard Deviation13,584,283
Sample Variance184.5T
Range47.3M
R-Value0.47
Mean Square Error153.9T
R-Squared0.23
Significance0.07
Slope1,442,048
Total Sum of Squares2583.5T

Galectin End Period Cash Flow History

202413.8 M
202325.7 M
202218.6 M
202139.6 M
202027.1 M
201947.5 M
20188.3 M

About Galectin Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Galectin Therapeutics income statement, its balance sheet, and the statement of cash flows. Galectin Therapeutics investors use historical funamental indicators, such as Galectin Therapeutics's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may use each financial statement separately, they are all related. The changes in Galectin Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Galectin Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Galectin Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Galectin Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow25.7 M13.8 M

Pair Trading with Galectin Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galectin Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galectin Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Galectin Stock

  0.87JNJ Johnson Johnson Aggressive PushPairCorr
  0.75EQ Equillium Earnings Call This WeekPairCorr
  0.7IQV IQVIA HoldingsPairCorr
  0.61KA Kineta IncPairCorr
  0.58CRL Charles River LaboraPairCorr
The ability to find closely correlated positions to Galectin Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galectin Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galectin Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galectin Therapeutics to buy it.
The correlation of Galectin Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galectin Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galectin Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Galectin Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Galectin Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Galectin Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Galectin Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Galectin Therapeutics Stock:
Check out the analysis of Galectin Therapeutics Correlation against competitors.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Galectin Stock analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Bonds Directory
Find actively traded corporate debentures issued by US companies
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Is Galectin Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galectin Therapeutics. If investors know Galectin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Return On Assets
(0.96)
Return On Equity
(37.28)
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galectin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.